The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
SBT-20
SS-20 is the compound that taught the field how SS-31 actually works. Its value to science is established. Its value to the community user — relative to its more extensively studied sister compound SS-31 — is the question this chapter can clarify but not fully answer.
The central tension resolved: SS-20 and SS-31 share cardiolipin-binding IMM targeting. SS-31 adds antioxidant chemistry (Dmt). SS-20 does not (Phe). In the Parkinson's model — where MPTP causes oxidative stress through Complex I inhibition — SS-20 and SS-31 were comparably neuroprotective. This finding established that the cardiolipin structural mechanism, not antioxidant scavenging, is the primary driver of SS peptide efficacy. SS-20 is a cleaner pharmacological probe of the structural mechanism; SS-31 is the compound with both the structural mechanism and the antioxidant chemistry add-on. SS-31 has Phase 2/3 clinical trials, FDA approval, and human tissue data. SS-20 has animal models and cell culture. For community use, SS-31 is the better-evidenced choice. For mechanistic curiosity about what the cardiolipin structural mechanism specifically does in your biology — SS-20 is the tool.
The strongest argument for SS-20: pure structural mechanism with no antioxidant chemistry confounds. In applications where the primary benefit of SS peptides is structural — cristae organization, ETC supercomplex stability, mitochondrial bioenergetics under chronic structural degradation — SS-20 may produce equivalent results to SS-31. Lower cost than SS-31. No Dmt oxidation concern in solution. Mechanistically clean.
The strongest argument for SS-31 over SS-20: more published evidence. Human clinical trial data. FDA approval for one indication. Siegel 2023 human ex vivo ADP sensitivity finding. The antioxidant chemistry dimension is likely additive in aging and metabolic disease contexts where oxidative stress contributes to pathology alongside structural mitochondrial decline. For most anti-aging and longevity applications, the combination of structural + antioxidant mechanisms in SS-31 is probably better than structural alone in SS-20.
When Hazel Szeto and Peter Schiller at Cornell were developing the SS peptide series in the early 2000s, they were guided by a design principle: alternating aromatic and cationic amino acid residues, creating a molecule that would accumulate in the negatively-charged inner mitochondrial membrane. The original mechanistic hypothesis was that the aromatic residues — particularly tyrosine derivatives like Dmt — would provide antioxidant activity once inside the IMM, scavenging the reactive oxygen species that mitochondria produce during oxidative phosphorylation. This was a reasonable hypothesis. It was also, as subsequent work would demonstrate, only part of the story.
The SS series produced several compounds with different aromatic residue compositions. SS-31 has the sequence D-Arg-Dmt-Lys-Phe-NH₂, where Dmt (2',6'-dimethyltyrosine) at position 2 provides well-documented free radical scavenging activity — the tyrosine's phenol ring directly neutralizes superoxide, hydrogen peroxide, and peroxynitrite. SS-20 has the sequence Phe-D-Arg-Phe-Lys-NH₂, where both aromatic positions are occupied by phenylalanine. Phenylalanine's benzene ring cannot scavenge free radicals — it lacks the phenol hydroxyl group that makes tyrosine and its derivatives antioxidants. SS-20 was the compound that made the field reconsider everything.
In the MPTP mouse model of Parkinson's disease — one of the most widely used neurotoxicity models — SS-31 produced robust neuroprotection of dopaminergic neurons. This was expected: SS-31's antioxidant activity should protect neurons from the oxidative stress that MPTP-induced Complex I inhibition causes. Then SS-20 was tested in the same model. SS-20, which cannot scavenge free radicals, produced comparable neuroprotection. Both compounds were effective. Both worked at nanomolar concentrations in preventing MPP+-induced cell death in dopaminergic cell cultures. Both prevented MPTP-induced inhibition of oxygen consumption and ATP production in isolated mitochondria. Both prevented mitochondrial swelling.
The mechanistic implication was significant: if SS-20, which lacks antioxidant chemistry, produces neuroprotection comparable to SS-31, then ROS scavenging cannot be the primary mechanism. Something about the interaction with the mitochondrial membrane itself — independent of antioxidant activity — must be the primary driver of the SS peptides' protective effects. This finding was foundational for the subsequent characterization of cardiolipin as the primary target, and the reframing of SS-31's mechanism from 'mitochondria-targeted antioxidant' to 'cardiolipin-binding membrane stabilizer.' SS-20 is the compound that did the mechanistic work of proving what SS-31 actually does.
THE CENTRAL TENSION
SS-20 and SS-31 are sister compounds from the same lab, the same design philosophy, and the same mitochondrial targeting mechanism. The community often treats them as interchangeable or views SS-20 as a weaker version of SS-31. The more accurate framing: SS-20 and SS-31 are pharmacological twins with different tools in their kit. SS-31 adds direct antioxidant chemistry (Dmt-mediated ROS scavenging) on top of the structural cardiolipin mechanism both compounds share. SS-20 uses only the structural mechanism. In conditions where oxidative stress is the primary driver of pathology, SS-31's antioxidant advantage may matter. In conditions where the primary problem is structural — cristae disorganization, ETC supercomplex destabilization, mitochondrial membrane potential collapse — both compounds may be equivalently effective because both address the root structural problem. SS-20 proved this. Whether that means SS-20 is appropriate for specific applications where SS-31's antioxidant activity is redundant or even unnecessary — that question has no human clinical data to answer it.
SS-20's evidence base is narrower than SS-31's — SS-31 has been through multiple Phase 2 and Phase 3 clinical trials across multiple indications. SS-20 has primarily animal and cell culture evidence. The disease models studied overlap substantially with SS-31's, and in many cases SS-20 was studied as the 'mechanistic control' compound — the non-antioxidant comparison that helped isolate which aspects of SS peptide efficacy require antioxidant chemistry vs structural membrane interaction.
The MPTP mouse model is the most widely used animal model of Parkinson's disease. MPTP crosses the blood-brain barrier and is metabolized to MPP+, which inhibits Complex I of the ETC in dopaminergic neurons, causing oxidative stress, mitochondrial dysfunction, and neuronal death that mimics the dopaminergic neuron loss of Parkinson's disease. Cho et al. (2007) [1] — published in Antioxidants & Redox Signaling — compared SS-31 and SS-20 in this model. Both peptides provided significant neuroprotection of dopaminergic neurons. Both prevented MPTP-induced striatal dopamine depletion. In cell culture (SN4741 dopaminergic cells), both SS-31 and SS-20 protected against MPP+-induced cell death at nanomolar concentrations. In isolated mitochondria, both prevented MPP+-induced inhibition of oxygen consumption and ATP production, and both prevented mitochondrial swelling. SS-20, which cannot scavenge ROS, was as effective as SS-31 in all of these measurements. This finding directly challenged the antioxidant mechanism hypothesis and provided the first clear evidence that the structural mechanism is primary. Grade B: published peer-reviewed data; multiple measurement approaches; mechanistically significant; single published study — needs replication for high confidence.
SS-20 (as SBT-20) has been studied in renal ischemia-reperfusion injury — the damage that occurs when blood supply is restored to the kidney after ischemia, as occurs during surgery and transplantation. SS-20 reduced tubular cell apoptosis, restored mitochondrial membrane potential, normalized electron transport chain function, and reduced interstitial fibrosis in the post-ischemic kidney. The mechanistic explanation: kidney tubular cells are among the most mitochondria-dense cells in the body; their vulnerability to ischemia-reperfusion is primarily mitochondrial; stabilizing IMM cardiolipin and preventing mPTP opening during reperfusion provides protection. The kidney I/R work with SS-20 parallels SS-31's kidney I/R data and provides further evidence that the structural mechanism is sufficient for renal protection. Grade B: multiple animal kidney I/R studies; SBT-20 alias appears in this literature; mechanistically coherent; no human kidney trial for SS-20 specifically.
The most consistently replicated finding across the entire SS peptide family — including SS-31, SS-20, and other SS analogs — is protection against ischemia-reperfusion injury in the heart. SS-20 reduces infarct size in cardiac I/R models through mitochondrial membrane stabilization, preservation of ETC function, and prevention of mPTP opening and cytochrome c release during reperfusion. The cardiac protection data for SS-20 is less extensive than for SS-31, but the consistent finding that SS-20 provides comparable protection to SS-31 in I/R models supports the structural mechanism interpretation. Grade C: animal I/R models; consistent with SS-31 data; mechanistically coherent; less published than SS-31's cardiac data.
SS-20 has been studied in other neurodegenerative contexts beyond the MPTP Parkinson's model. Neuroprotection against excitotoxicity, oxidative stress-induced neuronal death, and mitochondrial dysfunction-mediated neurodegeneration has been documented across multiple cell culture models. SS-20's protective effects in these models — where ROS is often implicated as a pathological driver — indicate that structural IMM stabilization provides meaningful neuroprotection even without direct antioxidant activity. Mechanistically: by preventing mPTP opening, cytochrome c release, and bioenergetic collapse, SS-20 interrupts the mitochondrial death cascade regardless of the upstream ROS trigger. Grade C: cell culture models; mechanistically coherent; limited published animal data beyond MPTP model.
SS-31's most compelling aging-relevant human data is from Siegel 2023 — the ex vivo ADP sensitivity finding in aging human skeletal muscle. No equivalent study exists for SS-20 in aging tissue. SS-20's structural mechanism should theoretically produce the same mitochondrial bioenergetic improvements in aging tissue, since cardiolipin peroxidation and ETC supercomplex destabilization occur in aging muscle through the same mechanisms that SS-20's cardiolipin stabilization addresses. Whether SS-20 or SS-31 is more effective for the aging tissue application — where both oxidative stress and structural degradation contribute to mitochondrial dysfunction — is not established. Grade D: mechanistic inference; no published aging-specific SS-20 study.
SS-20: Phe-D-Arg-Phe-Lys-NH₂. Four amino acids. Net charge +3 at physiological pH (from the guanidinium of D-Arg and the ε-amino of Lys, plus the N-terminal amino group of Phe). Molecular weight approximately 580 Da. The alternating aromatic/basic pattern (Phe-DArg-Phe-Lys) is the SS peptide design principle — aromatic residues intercalate into lipid membranes while basic residues interact electrostatically with negatively charged phospholipid headgroups (primarily cardiolipin's phosphate groups). The D-arginine at position 2 provides stereochemical resistance to aminopeptidase degradation — the same rational design choice as D-Arg in SS-31.
The critical residue comparison: SS-31 position 2 is 2',6'-dimethyltyrosine (Dmt) — a modified tyrosine where methyl groups at the 2' and 6' positions of the aromatic ring sterically protect the phenol hydroxyl group while enhancing radical scavenging capacity. SS-20 position 2 is phenylalanine — benzene ring, no hydroxyl group, no radical scavenging chemistry. This single change is what separates the two compounds pharmacologically. Everything else is structurally analogous.
THE DMT VS PHE DISTINCTION — THE WHOLE PHARMACOLOGICAL STORY
Dimethyltyrosine (SS-31) has a phenol hydroxyl group (-OH) that donates hydrogen atoms to reactive oxygen species, neutralizing them. The resulting tyrosyl radical is stabilized and relatively unreactive. Phenylalanine (SS-20) has only a benzene ring (-H at all positions). No hydroxyl group. No radical donation. No antioxidant activity. This is why SS-20 cannot scavenge ROS — the chemistry simply isn't there. It also means SS-20's entire protective effect must come from membrane interaction and structural cardiolipin stabilization. When SS-20 proves effective in disease models, it demonstrates that this structural mechanism alone is sufficient for protection. When SS-31 proves more effective than SS-20 in models with high oxidative stress burden, it demonstrates that the antioxidant chemistry adds additional benefit on top of the structural mechanism.
SS-20 accumulates in the inner mitochondrial membrane through the same two driving forces as SS-31: (1) the large mitochondrial membrane potential (~180 mV negative inside the matrix, relative to the cytoplasm) electrostatically concentrates the positively charged peptide within mitochondria — 1,000-5,000x above extramitochondrial concentrations; (2) the aromatic Phe residues intercalate into the lipid membrane interface, providing additional binding energy beyond electrostatics. The result is the same IMM targeting behavior as SS-31, at similar concentrations, through the same physics.
The eLife 2022 [3] structure-activity relationship (SAR) study provided atomic-level characterization of how SS peptides interact with cardiolipin-containing membranes. SS-20's Phe/Phe aromatic composition produces a different membrane orientation than SS-31's Dmt/Phe composition — the two phenyl groups interact with the membrane interface differently than Dmt/Phe, potentially producing subtly different geometries of interaction with cardiolipin's two phosphate groups and four acyl chains. The cardiolipin binding is confirmed for SS-20 — both electrostatic (through the cationic residues) and hydrophobic (through the aromatic rings). The quantitative difference in cardiolipin binding affinity between SS-20 and SS-31 has not been definitively characterized at the molecular level.
SS-20 = SBT-20 in some clinical and regulatory contexts (SBT is the corporate identifier used in some pharmaceutical development documents). Like SS-31's multiple names (Elamipretide/Bendavia/MTP-131), the dual naming reflects the transition from academic research compound to clinical development candidate. Most published literature uses SS-20; some kidney disease clinical development literature uses SBT-20. Same compound. Research chemical vendors typically list it as SS-20. COA mass spectrometry should confirm ~580 Da.
SS-20: lyophilized powder reconstituted with bacteriostatic water. Refrigerate at 2-8C after reconstitution; use within 30 days. SS-20 lacks the Dmt residue's oxidation risk — the standard Dmt antioxidant consumption concern for SS-31 in solution does not apply to the same degree for SS-20's Phe residues. Standard cold-chain storage applies nonetheless. HPLC purity 98%+. Mass spectrometry confirming ~580 Da is the identity check. Pricing 2026: research vendor, 10 mg SS-20: $40-90.
SS-20's mechanism is, in a sense, a cleaner version of SS-31's mechanism — it performs only the structural cardiolipin-binding, membrane-stabilizing work, without the additional antioxidant chemistry layer. Understanding SS-20 is understanding what the SS peptide structural mechanism does independent of any radical scavenging.
SS-20 accumulates in the inner mitochondrial membrane at 1,000-5,000x extramitochondrial concentrations, driven by membrane potential and cardiolipin affinity — the same mechanism as SS-31. This is not in question; it has been confirmed in multiple cell and mitochondria preparations. The accumulation is energy-dependent (membrane potential drives it) but non-saturable (there is no classical receptor with a finite binding capacity — the binding site is the membrane itself). Grade B: well-established from SS peptide family studies; extrapolated to SS-20 based on structural analogies and direct measurements in cell preparations.
By binding cardiolipin in the IMM — the structural phospholipid that organizes ETC supercomplexes and maintains cristae architecture — SS-20 modulates the biophysical properties of the membrane in ways that stabilize the cristae geometry required for efficient ETC operation. This is the mechanism that SS-20 shares with SS-31. The eLife 2022 SAR study confirmed that this structural interaction, not antioxidant chemistry, is the primary driver of cytoprotection across the SS peptide series. SS-20's Phe/Phe composition interacts with the cardiolipin-containing membrane via the same electrostatic (cationic residues to phosphate headgroups) and hydrophobic (aromatic rings to acyl chain interface) forces, though possibly with different geometric details than SS-31's Dmt/Phe composition. Grade B-C: structural mechanism confirmed; cardiolipin binding documented; specific geometric differences from SS-31 at the molecular level not fully resolved.
SS-20 does not scavenge free radicals. This is not a limitation or a deficiency — it is a structural fact. Phenylalanine's benzene ring cannot donate hydrogen atoms to neutralize reactive oxygen species. This has been confirmed in direct antioxidant assays: SS-20 does not scavenge superoxide, hydrogen peroxide, or peroxynitrite in vitro at concentrations where SS-31 does. SS-20's protective effects are entirely attributable to membrane structural mechanisms. Grade A: structural chemistry is unambiguous; direct experimental confirmation in antioxidant assays.
Through cardiolipin stabilization and ETC supercomplex preservation, SS-20 improves the efficiency of electron transfer through the respiratory chain, reduces electron leak (the source of mitochondrial superoxide production), and increases ATP synthesis rates. These downstream bioenergetic improvements are the same category of effects produced by SS-31 through its cardiolipin mechanism — and in models where SS-20 has been compared directly to SS-31, the two compounds often produce comparable bioenergetic improvements despite SS-20's lack of antioxidant chemistry. This is the core mechanistic finding: bioenergetic improvement does not require antioxidant activity; it requires structural cardiolipin stabilization. Grade B-C: consistent animal model findings; limited direct head-to-head comparison data.
By preserving mitochondrial membrane potential, preventing mitochondrial permeability transition pore (mPTP) opening, reducing cytochrome c release, and maintaining ETC function under stress, SS-20 provides broad cytoprotection — the same downstream protective cascade as SS-31. In cell death assays using multiple cytotoxic insults, SS-20 prevented mitochondrial dysfunction-mediated apoptosis at nanomolar concentrations. The mechanism: by stabilizing the IMM architecture, SS-20 prevents the cascade of events (CL peroxidation → cytochrome c dissociation → mPTP opening → apoptosis) that unfolds when mitochondria are stressed. Grade B: multiple independent cell culture models; MPTP animal model; mechanistically coherent with cardiolipin structural role.
SS-20's gene expression effects, like SS-31's, are secondary to its structural mitochondrial mechanism rather than direct transcriptional activation. By improving mitochondrial bioenergetics, SS-20 reduces the cellular stress burden that drives inflammatory gene expression (NF-κB pathway), improves the energy availability for normal transcriptional programs, and supports mitochondrial biogenesis signaling through PGC-1α (which requires adequate mitochondrial function to be effectively translated into new mitochondria). The absence of Dmt means SS-20 lacks any potential for Dmt-mediated radical scavenging effects on DNA damage, which could theoretically affect DNA repair gene expression. Whether this matters clinically is unknown — but it is a mechanistic distinction from SS-31 at the transcriptional level as well as the antioxidant level. No dedicated transcriptomic study of SS-20 vs SS-31 in human or animal tissue has been published.
THE SS-20 EVIDENCE ARCHITECTURE VS SS-31
SS-31 has Phase 2 and Phase 3 clinical trial data across multiple indications — Barth syndrome (FORZINITY approval), heart failure (PROGRESS-HF), mitochondrial myopathy (MMPOWER-3). SS-20 has none. The clinical evidence for the SS peptide class is entirely SS-31's evidence. SS-20's evidence base is animal models and cell culture. This is not a criticism — SS-20 served a critical scientific function as the mechanistic control compound that elucidated SS-31's true mechanism. But it means that anyone using SS-20 is using a compound whose human pharmacology is entirely uncharacterized, while a closely related compound (SS-31/Elamipretide) has extensive human trial data. The rational question: why use SS-20 rather than SS-31? The answer depends on what the user is specifically trying to accomplish and whether the antioxidant chemistry dimension of SS-31 is relevant to their situation.
Application
Evidence Type
Grade
Key Finding
SS-31 Comparison
Parkinson's/dopaminergic neuroprotection
Animal (MPTP model) + cell culture
B
SS-20 ≈ SS-31 efficacy despite no antioxidant activity; proves structural mechanism primary
SS-31 has more extensive published data; no head-to-head advantage for either
Kidney ischemia-reperfusion
Animal models (SBT-20 alias)
B
Reduced tubular injury, restored mitochondrial function, reduced fibrosis
SS-31 more extensively studied; similar mechanisms expected
Cardiac ischemia-reperfusion
Animal models
C
Protection comparable to other SS peptides
SS-31 has more published cardiac data including some human-adjacent data
Aging mitochondrial function
Mechanistic inference
D
Theoretical application based on cardiolipin mechanism
SS-31 has Siegel 2023 human ex vivo ADP sensitivity data — stronger evidence
Human clinical benefit (any)
None
X
No human trial for SS-20/SBT-20
SS-31 has Phase 2/3 human data and FDA approval for Barth syndrome
| Application | Evidence level | Grade | Confidence | Key limitation |
|---|---|---|---|---|
| Parkinson's/dopaminergic neuroprotection | Animal (MPTP model) + cell culture | B | SS-20 ≈ SS-31 efficacy despite no antioxidant activity; proves structural mechanism primary | SS-31 has more extensive published data; no head-to-head advantage for either |
| Kidney ischemia-reperfusion | Animal models (SBT-20 alias) | B | Reduced tubular injury, restored mitochondrial function, reduced fibrosis | SS-31 more extensively studied; similar mechanisms expected |
| Cardiac ischemia-reperfusion | Animal models | C | Protection comparable to other SS peptides | SS-31 has more published cardiac data including some human-adjacent data |
| Aging mitochondrial function | Mechanistic inference | D | Theoretical application based on cardiolipin mechanism | SS-31 has Siegel 2023 human ex vivo ADP sensitivity data — stronger evidence |
| Human clinical benefit (any) | None | X | No human trial for SS-20/SBT-20 | SS-31 has Phase 2/3 human data and FDA approval for Barth syndrome |
DOSING CONTEXT — FOLLOWING SS-31 AS REFERENCE
SS-20 has no validated human dose. No pharmacokinetic study has been published for SS-20 in humans or in non-human primates. Community protocols are derived by analogy from SS-31's clinical trial dosing (40 mg/day for Barth syndrome) scaled down to the community-standard 5-10 mg/day range, then applied to SS-20 based on structural similarity. Whether the same dose produces the same IMM concentration for SS-20 vs SS-31 — given their slight molecular weight difference (~580 Da vs ~639 Da) and potentially different membrane partitioning characteristics — is unknown.
Adjust any input. The syringe draw updates live. Tap a preset row to load that dilution.
| BAC | Concentration | Per unit | Notes |
|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 1 mcg | Standard |
| 5 mL | 2,000 mcg/mL | 2.5 mcg | Lower concentration; larger injection volume |
| 1 mL | 5,000 mcg/mL | 1 mcg | Smaller vial |
SS-20's pharmacokinetics are inferred from SS-31's published data and structural similarity. Plasma half-life: estimated at 30-60 minutes after SubQ injection (comparable to SS-31). IMM accumulation: 1,000-5,000x extramitochondrial, driven by membrane potential (same physics as SS-31). Tissue distribution: highest in mitochondria-dense tissues (heart, skeletal muscle, kidney, brain). No oxidation risk from Dmt (unlike SS-31, where the Dmt residue can be consumed by ROS in solution and in vivo). This last point means SS-20 may have slightly better solution stability than SS-31 — but the pharmacological relevance of this difference for the community user is unknown.
SS-20: lyophilized powder reconstituted with bacteriostatic water. Solution is clear and colorless. Refrigerate at 2-8C after reconstitution; use within 30 days. No Dmt oxidation concern — standard reconstitution without special precautions for air exposure. Mass spectrometry confirming ~580 Da is the identity check. HPLC purity 98%+. Pricing 2026: research vendor (HPLC + MS + endotoxin COA), 10 mg SS-20: $40-90.
Vial Size
BAC Water
Concentration
Volume for 5 mg
Notes
10 mg
2.0 mL
5,000 mcg/mL
1.0 mL (100 units)
Standard
10 mg
5.0 mL
2,000 mcg/mL
2.5 mL
Lower concentration; larger injection volume
5 mg
1.0 mL
5,000 mcg/mL
1.0 mL (full vial)
Smaller vial
Protocol
Dose
Frequency
Notes
Conservative / entry
2-5 mg SubQ
Daily
Starting point; assess response vs SS-31 experience
Standard community
5-10 mg SubQ
Daily, 5-7x/week
Mirrors SS-31 community protocol
SS-31 clinical reference
40 mg
Daily SubQ
FORZINITY/Barth syndrome approved dose — 4-8x above community doses
The evidence does not clearly support choosing SS-20 over SS-31 for most applications, because SS-31 has both the structural cardiolipin mechanism AND the antioxidant chemistry, while SS-20 has only the structural mechanism. The rational cases for choosing SS-20 over SS-31:
SS-20's safety profile in published animal studies is comparable to SS-31's — no significant adverse effects documented in the models studied. No published human safety study for SS-20 exists. Community safety reports are sparse given the smaller user base, but consistent with a clean profile similar to SS-31. The absence of Dmt means some potential SS-31-specific concerns (Dmt-related immunogenicity, Dmt oxidation products) may not apply to SS-20 — but new concerns specific to SS-20's Phe/Phe structure are equally uncharacterized.
SS-31's FORZINITY prescribing information documents hypersensitivity reactions as a warning (urticaria, angioedema). Whether SS-20 carries the same risk is unknown. The Dmt residue in SS-31 creates a non-standard chemical moiety that could serve as a novel antigenic epitope; SS-20's phenylalanine is a standard amino acid with lower immunogenic novelty. This reasoning suggests SS-20 might have a slightly lower hypersensitivity risk than SS-31 — but this is speculative inference from molecular structure, not clinical evidence.
Not FDA-approved. Not PCAC-reviewed. Research chemical only. Not a controlled substance. Not listed on the 2026 WADA Prohibited List. Unlike SS-31, which was approved as FORZINITY in September 2025 (creating some regulatory complexity for research chemical SS-31), SS-20 has no pharmaceutical development history that would affect its research chemical regulatory status. It remains a pure research compound.
SS-20's stacking logic is identical to SS-31's with one modification: because SS-20 lacks antioxidant chemistry, its combination with compounds that address oxidative stress is more clearly additive rather than potentially redundant.
MOTS-c drives AMPK-mediated metabolic signaling. SS-20 stabilizes IMM structure. These mechanisms are non-redundant regardless of SS-20's antioxidant status. The mitochondrial pair argument applies: SS-20 as structural hardware, MOTS-c as metabolic software. Unlike combining SS-31 with MOTS-c (where some question exists about whether SS-31's antioxidant activity could affect MOTS-c's AICAR-mediated AMPK pathway), SS-20 has no antioxidant layer that could complicate the combination.
NAD+ supports the bioenergetic function that SS-20 is trying to optimize. SS-20 stabilizes the physical architecture of the ETC; NAD+ ensures the cofactor supply for that ETC to operate. Same mechanistic logic as SS-31 + NAD+, with the same non-redundancy argument. Both can be run continuously rather than cycled.
The community occasionally stacks SS-20 and SS-31 together. The mechanistic argument for this combination is weak — both compounds work through cardiolipin binding and IMM structural stabilization. Combining them is likely to produce receptor saturation or redundant target occupancy rather than additive benefit. Choose one or the other; if exploring which mechanism matters more for your specific situation, alternate cycles rather than run simultaneously.
Because SS-20 lacks antioxidant chemistry, combining it with a mitochondria-targeted antioxidant (MitoQ, which is a plastiquinone antioxidant) is mechanistically complementary rather than redundant. SS-20 provides structural membrane stabilization; MitoQ provides the antioxidant ROS scavenging that SS-20 is missing. This combination would theoretically recapitulate what SS-31 does — structural mechanism plus antioxidant chemistry — using two separate compounds. Whether this combination produces additive benefit over SS-31 alone, SS-20 alone, or MitoQ alone is not established.
No dramatic acute effects expected — consistent with structural mechanism. Mild energy improvement possible. No injection site reactions more frequent than SS-31.
Exercise recovery and energy stability improvements — the most commonly reported community benefit. Comparable to SS-31 experience.
Sustained metabolic improvements in users with baseline mitochondrial compromise. No dramatic landmark events expected.
Given the very small community using SS-20 specifically, the timeline data is even more limited than for SS-31. Community users who have switched from SS-31 to SS-20 or run them in alternation report qualitatively similar effects to SS-31 — improved energy and exercise recovery being the most consistent reports. Some users describe SS-20's effect as 'similar but slightly less pronounced' than SS-31; others report no perceptible difference. This variation is consistent with both genuine pharmacological differences and expectation effects in a small, self-selecting community.
Timeframe
Expected (Based on SS-31 Analog Data, Grade D-E)
Days 1-7
No dramatic acute effects expected — consistent with structural mechanism. Mild energy improvement possible. No injection site reactions more frequent than SS-31.
Week 2-4
Exercise recovery and energy stability improvements — the most commonly reported community benefit. Comparable to SS-31 experience.
Month 1+
Sustained metabolic improvements in users with baseline mitochondrial compromise. No dramatic landmark events expected.
The most practically useful information for someone choosing between SS-20 and SS-31 is community comparative experience. The consensus is limited but directionally consistent: SS-20 and SS-31 appear to produce similar quality of effect (energy, recovery, exercise performance) with slightly less pronounced magnitude for SS-20 in most reports. Whether this reflects a true pharmacological difference (SS-31's antioxidant chemistry adding value) or a placebo expectation effect (SS-20 is described as 'lesser' so users expect less) cannot be determined from community self-reports. The mechanistic prediction: in conditions with significant oxidative stress burden (metabolic syndrome, post-chemotherapy, high-intensity exercise), SS-31's antioxidant advantage may produce measurably better outcomes. In conditions where the primary problem is structural mitochondrial disorganization without prominent oxidative stress, SS-20 may be equivalent.
No established cycling requirement for SS-20 beyond what applies to SS-31. Daily continuous dosing is the community standard, consistent with the SS-31 clinical trial approach and the logic of continuous structural membrane support.
SS-20 occupies an even more niche position than SS-31 in the research peptide community. Its users are almost exclusively people who have already used SS-31 and are curious about the mechanistic comparison, or researchers interested in the structure-activity relationship question. The community is small, technically engaged, and generally sophisticated about the mechanistic distinction. No significant adverse event reporting exists in this small community, consistent with the animal safety profile.
The honest position on SS-20 in 2026: the compound that proved how SS-31 works. Its scientific contribution is primarily mechanistic — it was the control experiment that clarified the primary mechanism of the entire SS peptide class. As a therapeutic compound for community use, it offers the structural cardiolipin mechanism without the antioxidant chemistry; whether that tradeoff is beneficial, neutral, or disadvantageous for specific applications depends on the relative contributions of structural vs oxidative pathology in those applications — a question that requires human clinical data to answer, and that data does not exist for SS-20.
Research provenance: SS-20's published literature is primarily from the Szeto group (Cornell/Weill Cornell) and from researchers using SS-20 as a mechanistic tool. Unlike the SS-31 literature (which includes independent groups at University of Washington, Johns Hopkins, and others), SS-20 publications are more concentrated in the original research group. The Cho 2007 [2] paper is the most important independent SS-20 study.
Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK. (2007). Potent mitochondria-targeted peptides reduce myocardial infarction in rats. Coron Artery Dis. 18(3):215-20. PMID: 17429293. [SS-20 and SS-31 directly compared in ischemia-reperfusion; both protective; non-antioxidant SS-20 efficacy indicates structural mechanism primary]
Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. (2007). A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J Biol Chem. [MPTP Parkinson's model comparison: both SS-31 and SS-20 neuroprotective at nM concentrations despite SS-20 lacking antioxidant activity; PMC2819801; foundational mechanistic evidence]
eLife. (2022). Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds. doi:10.7554/eLife.75531. PMC9451972. [Comprehensive SAR study of SS peptides including SS-20; Phe/Phe composition vs Dmt/Phe; cardiolipin interaction characterized; confirms SS-20 lacks ROS scavenging; structural binding geometry analyzed at atomic level; multiple independent groups]
PMC7585075. (2020) [4]. The mitochondrial-targeted peptide SBT-20 ameliorates inflammation and oxidative stress in chronic renal failure. [SS-20 = SBT-20 confirmed; kidney ischemia-reperfusion protection; restored mitochondrial function; reduced fibrosis; Szeto group]
Szeto HH. (2014) [5]. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 171(8):2029-50. PMID: 24117051. [Comprehensive Szeto review of SS peptide series including SS-20 and SS-31; cardiolipin mechanism established; historical context for the antioxidant → structural mechanism evolution]
PMC4921212. (2016) [6]. Mitochondria-Targeted Antioxidant SS-31 is a Potential Novel Ophthalmic Medication for Neuroprotection in Glaucoma. [Describes SS-02, SS-31, and SS-20 as three compounds in the series; confirms all three carry 3+ net charge; IMM accumulation documented]
PMC11409442 (RSC Advances). (2024) [7]. Discovery of novel SS-31 derivatives as potent agents to ameliorate inflammation and increase mitochondrial ATP synthesis. [Notes that SS-20 'may lack the refined targeting and enhanced stability exhibited by SS-31'; derivative chemistry context]
SS-20 is the compound that taught the field how SS-31 actually works. Its value to science is established. Its value to the community user — relative to its more extensively studied sister compound SS-31 — is the question this chapter can clarify but not fully answer.
The central tension resolved: SS-20 and SS-31 share cardiolipin-binding IMM targeting. SS-31 adds antioxidant chemistry (Dmt). SS-20 does not (Phe). In the Parkinson's model — where MPTP causes oxidative stress through Complex I inhibition — SS-20 and SS-31 were comparably neuroprotective. This finding established that the cardiolipin structural mechanism, not antioxidant scavenging, is the primary driver of SS peptide efficacy. SS-20 is a cleaner pharmacological probe of the structural mechanism; SS-31 is the compound with both the structural mechanism and the antioxidant chemistry add-on. SS-31 has Phase 2/3 clinical trials, FDA approval, and human tissue data. SS-20 has animal models and cell culture. For community use, SS-31 is the better-evidenced choice. For mechanistic curiosity about what the cardiolipin structural mechanism specifically does in your biology — SS-20 is the tool.
The strongest argument for SS-20: pure structural mechanism with no antioxidant chemistry confounds. In applications where the primary benefit of SS peptides is structural — cristae organization, ETC supercomplex stability, mitochondrial bioenergetics under chronic structural degradation — SS-20 may produce equivalent results to SS-31. Lower cost than SS-31. No Dmt oxidation concern in solution. Mechanistically clean.
The strongest argument for SS-31 over SS-20: more published evidence. Human clinical trial data. FDA approval for one indication. Siegel 2023 human ex vivo ADP sensitivity finding. The antioxidant chemistry dimension is likely additive in aging and metabolic disease contexts where oxidative stress contributes to pathology alongside structural mitochondrial decline. For most anti-aging and longevity applications, the combination of structural + antioxidant mechanisms in SS-31 is probably better than structural alone in SS-20.
SS-20 is the compound that taught the field how SS-31 actually works. Its value to science is established. Its value to the community user — relative to its more extensively studied sister compound SS-31 — is the question this chapter can clarify but not fully answer.
The central tension resolved: SS-20 and SS-31 share cardiolipin-binding IMM targeting. SS-31 adds antioxidant chemistry (Dmt). SS-20 does not (Phe). In the Parkinson's model — where MPTP causes oxidative stress through Complex I inhibition — SS-20 and SS-31 were comparably neuroprotective. This finding established that the cardiolipin structural mechanism, not antioxidant scavenging, is the primary driver of SS peptide efficacy. SS-20 is a cleaner pharmacological probe of the structural mechanism; SS-31 is the compound with both the structural mechanism and the antioxidant chemistry add-on. SS-31 has Phase 2/3 clinical trials, FDA approval, and human tissue data. SS-20 has animal models and cell culture. For community use, SS-31 is the better-evidenced choice. For mechanistic curiosity about what the cardiolipin structural mechanism specifically does in your biology — SS-20 is the tool.
The strongest argument for SS-20: pure structural mechanism with no antioxidant chemistry confounds. In applications where the primary benefit of SS peptides is structural — cristae organization, ETC supercomplex stability, mitochondrial bioenergetics under chronic structural degradation — SS-20 may produce equivalent results to SS-31. Lower cost than SS-31. No Dmt oxidation concern in solution. Mechanistically clean.
The strongest argument for SS-31 over SS-20: more published evidence. Human clinical trial data. FDA approval for one indication. Siegel 2023 human ex vivo ADP sensitivity finding. The antioxidant chemistry dimension is likely additive in aging and metabolic disease contexts where oxidative stress contributes to pathology alongside structural mitochondrial decline. For most anti-aging and longevity applications, the combination of structural + antioxidant mechanisms in SS-31 is probably better than structural alone in SS-20.
Feature
SS-20
SS-31 (Elamipretide)
Sequence
Phe-D-Arg-Phe-Lys-NH₂
D-Arg-Dmt-Lys-Phe-NH₂
Molecular weight
~580 Da
~639 Da
Position 2 residue
Phe (no antioxidant)
Dmt (potent antioxidant)
Direct ROS scavenging
None — structurally impossible
Yes — Dmt-mediated
Cardiolipin binding
Confirmed — electrostatic + hydrophobic
Confirmed — same mechanism + Dmt modification
IMM accumulation
1,000-5,000x — same as SS-31
1,000-5,000x
Net charge at pH 7.4
+3
+3
Human clinical trials
None
Phase 2/3 across multiple indications
FDA approval
None
FORZINITY — Barth syndrome (September 2025)
Human ex vivo data
None
Siegel 2023 — ADP sensitivity in aging human muscle
WADA status
Not listed
Not listed
Primary scientific value
Proved structural mechanism is primary for SS class
Clinical-stage therapeutic with established mechanism
Community evidence grade
E (very small community)
B-C (more established community use + clinical trial analog)
Cost (approximate)
$40-90/10 mg
$60-120/10 mg
Oxidation stability in solution
Better (no Dmt)
Standard (Dmt can oxidize)
— End of SS-20 —
THE PEPTIDE BIBLE | SS-20 (SBT-20) | For Research & Educational Purposes Only
SS-20 (SBT-20) is a Szeto-Schiller (SS) tetrapeptide: Phe-D-Arg-Phe-Lys-NH₂. Molecular weight ~580 Da. Net charge +3 at physiological pH. Sister compound to SS-31 (Elamipretide) from the same Hazel Szeto/Peter Schiller research program at Cornell/Weill Cornell. Key structural difference: SS-20 has phenylalanine (Phe) at position 2; SS-31 has dimethyltyrosine (Dmt) at position 2. Dmt scavenges free radicals; Phe does not. SS-20 therefore lacks direct antioxidant chemistry — confirmed in direct antioxidant assays. Despite lacking antioxidant activity, SS-20 accumulates in the inner mitochondrial membrane via membrane potential (1,000-5,000x extramitochondrial concentration) and binds cardiolipin through the same electrostatic/hydrophobic mechanism as SS-31. The MPTP Parkinson's mouse model comparison (Cho et al., 2007, PMC2819801) demonstrated that SS-20 and SS-31 produce comparable neuroprotection at nanomolar concentrations — SS-20, which cannot scavenge ROS, was as effective as SS-31 in preventing dopaminergic neuronal death, ATP production loss, and mitochondrial swelling. This finding was mechanistically foundational: it proved that the cardiolipin structural interaction, not antioxidant chemistry, is the primary mechanism of the SS peptide class. SS-20 thus served the scientific function of demonstrating how SS-31 actually works. Other documented SS-20 applications: kidney ischemia-reperfusion protection (SBT-20 alias), cardiac ischemia-reperfusion protection, additional neuroprotective cell culture models. Structure-activity relationship: eLife 2022 SAR paper confirmed SS-20's Phe/Phe composition interacts with cardiolipin via structural forces without radical scavenging capability. Evidence summary: no human clinical trials for SS-20; SS-31 has Phase 2/3 data and FDA approval (FORZINITY, Barth syndrome 2025). Community dosing: 5-10 mg SubQ daily (mirroring SS-31 protocols by analogy). FDA: not approved; research chemical only. WADA: not listed. SS-20's pharmacological niche: the pure structural cardiolipin mechanism without antioxidant chemistry — cleaner mechanistic probe of what SS-31's non-antioxidant component does, potentially equivalent in conditions where structural dysfunction dominates, likely inferior to SS-31 in conditions with significant oxidative stress burden.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.